These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12534149)

  • 1. The epidermal growth factor receptor as a novel target for cancer therapy: case studies and clinical implications.
    Riddle J; Lee P; Purdom M
    Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):11-9. PubMed ID: 12534149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
    Thomas M
    Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):20-7. PubMed ID: 12534150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the epidermal growth factor receptor as a target for cancer therapy.
    Wood LS
    Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):3-10. PubMed ID: 12534148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epidermal growth factor receptor in lung cancer.
    Baselga J; Albanell J
    Curr Oncol Rep; 2002 Jul; 4(4):317-24. PubMed ID: 12044241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor-directed therapy in esophageal cancer.
    Pande AU; Iyer RV; Rani A; Maddipatla S; Yang GY; Nwogu CE; Black JD; Levea CM; Javle MM
    Oncology; 2007; 73(5-6):281-9. PubMed ID: 18477853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
    Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).
    Tseng YH; Hung HY; Sung YC; Tseng YC; Lee YC; Whang-Peng J; Chen YM
    J Chemother; 2016; 28(1):50-8. PubMed ID: 25976428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
    Hollywood E
    Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
    Chen WQ; Li P; Wang Q; Zhang YJ; Li HY; Jin XT; Yan S; Kou GF; Cai SL; Liu G
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):133-137. PubMed ID: 29502374
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted therapy: an evolving world of lung cancer.
    Lam KC; Mok TS
    Respirology; 2011 Jan; 16(1):13-21. PubMed ID: 20723139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor.
    Créquit P; Trinquart L; Ravaud P
    BMJ Open; 2016 Aug; 6(8):e011841. PubMed ID: 27489157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
    Herbst RS
    Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
    Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
    Haspinger ER; Garassino MC; Torri V; Cinquini M; De Braud F; Gelsomino F
    J Clin Oncol; 2014 Mar; 32(8):859-63. PubMed ID: 24493720
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.